Evidence summary for sclerotherapy and embolization outcomes/complications

in Vascular Malformations

Applied

Type

Addition

Confidence

65%

Created

Mar 19, 2026

Evidence

1 source

Rationale

The integration adds a specific clinical nuance regarding the recurrence of slow-flow malformations (specifically orbital venolymphatic lesions) based on the Cohen 2021 study. This study suggests that for certain distensible lesions, a combined surgical and endovascular approach may yield better long-term outcomes than sclerotherapy alone. I also expanded all required abbreviations on first use within the section to comply with the style guide.

Evidence

Cohen LM, et al. Recurrence of Distensible Orbital Venous-dominant Venolymphatic Malformations After Sclerotherapy Versus Embolization With Excision. Ophthalmic Plast Reconstr Surg. 2021. PMID: 34798656.
Verified source
PubMedDOI

Content Changes

<!-- type: evidence-summary -->

**What outcomes to expect (practical framing)**

- **AVM**Arteriovenous malformation (AVM) embolization:** durable control depends on **nidus-directed therapy**; staged sessions are common. Ethanol can be effective in experienced centers but carries higher complication risk and requires meticulous technique and monitoring. [@yakes1996] [@puig2010]
- **Slow-flow malformations:** sclerotherapy provides symptom improvement for many patients; multiple sessions are often required, and agent selection should be individualized by lesion morphology and anatomic risk. [@horbach2016] [@lee2014] In specific anatomical locations, such as orbital venolymphatic malformations, recurrence rates may be higher with sclerotherapy alone compared to combined embolization and surgical excision. [@cohen2021]

**Agent comparison (high-yield)**

| Lesion type | Common agents | Typical goal | Key safety consideration |
| --- | --- | --- | --- |
| AVM (fast-flow) | Ethanol, NBCA,n-butyl EVOHcyanoacrylate (NBCA), ethylene vinyl alcohol copolymer (EVOH) | Nidus eradication / flow reduction | Non-target embolization, skin/nerve injury; staging reduces necrosis/systemic toxicity. [@yakes1996] [@puig2010] |
| Venous malformation (slow-flow) | Polidocanol, STSsodium tetradecyl sulfate (STS) | Symptom relief, volume reduction | Skin injury, thrombosis; image guidance improves precision. [@horbach2016] |
| Lymphatic malformation | Doxycycline, bleomycin (center-dependent) | Cyst sclerosis and decompression | Swelling, infection risk; airway risk in cervicofacial disease. [@puig2010] |
Go to section in textbookDispute / Submit evidenceAll updates